Our top pick for
Building a portfolio
Auris Medical Holding Ltd is a biotechnology business based in the US. Auris Medical Holding shares (EARS) are listed on the NASDAQ and all prices are listed in US Dollars. Auris Medical Holding employs 8 staff and has a market cap (total outstanding shares value) of USD$41.3 million.
|52-week range||USD$0.7227 - USD$5.54|
|50-day moving average||USD$3.6554|
|200-day moving average||USD$2.1937|
|Wall St. target price||USD$14.95|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-1.327|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Valuing Auris Medical Holding stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Auris Medical Holding's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Auris Medical Holding's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 3x. In other words, Auris Medical Holding shares trade at around 3x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
|Gross profit TTM||USD$0|
|Return on assets TTM||-35.36%|
|Return on equity TTM||-84.67%|
|Market capitalisation||USD$41.3 million|
TTM: trailing 12 months
There are currently 110,901 Auris Medical Holding shares held short by investors – that's known as Auris Medical Holding's "short interest". This figure is 295% up from 28,075 last month.
There are a few different ways that this level of interest in shorting Auris Medical Holding shares can be evaluated.
Auris Medical Holding's "short interest ratio" (SIR) is the quantity of Auris Medical Holding shares currently shorted divided by the average quantity of Auris Medical Holding shares traded daily (recently around 1.2 million). Auris Medical Holding's SIR currently stands at 0.09. In other words for every 100,000 Auris Medical Holding shares traded daily on the market, roughly 90 shares are currently held short.
However Auris Medical Holding's short interest can also be evaluated against the total number of Auris Medical Holding shares, or, against the total number of tradable Auris Medical Holding shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Auris Medical Holding's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Auris Medical Holding shares in existence, roughly 10 shares are currently held short) or 0.0101% of the tradable shares (for every 100,000 tradable Auris Medical Holding shares, roughly 10 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Auris Medical Holding.
Find out more about how you can short Auris Medical Holding stock.
We're not expecting Auris Medical Holding to pay a dividend over the next 12 months.
Auris Medical Holding's shares were split on a 1:20 basis on 30 April 2019. So if you had owned 20 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Auris Medical Holding shares – just the quantity. However, indirectly, the new 1900% higher share price could have impacted the market appetite for Auris Medical Holding shares which in turn could have impacted Auris Medical Holding's share price.
Over the last 12 months, Auris Medical Holding's shares have ranged in value from as little as $0.7227 up to $5.54. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Auris Medical Holding's is 1.1977. This would suggest that Auris Medical Holding's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Auris Medical Holding Ltd. , a development-stage biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment and prevention of peripheral and central nervous disorders. The company's Phase 3 programs under the development include Keyzilen (AM-101) for the treatment of acute inner ear tinnitus; and Sonsuvi (AM-111) for the treatment of acute inner ear hearing loss. It is also developing AM-125 that is in Phase 2 clinical trial for the intranasal treatment of acute peripheral vertigo; and AM-201, which is in Phase 1b clinical trial for the prevention of weight gain and drowsiness, which are side effects of various antipsychotic drugs, as well as AM-102 for the tinnitus treatment. The company has a collaboration and license agreement with INSERM; and Xigen S. A. to develop, manufacture, and commercialize pharmaceutical products, as well as drug delivery devices and formulations for local administration of therapeutic substances to the inner ear for the treatment of ear disorders.
Steps to owning and managing ZTO, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZOM, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZI, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZKIN, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZION, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZIONL, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZNTL, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZGYH, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZEAL, with 24-hour and historical pricing before you buy.
Steps to owning and managing CTIB, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.